{"analyses":[{"ciLowerLimit":"0.45","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.83","estimateComment":"From a Cox Model stratified by tumor sidedness (left vs. right) and prior lines of therapy (0, 1, \\>= 2) as entered into the IRT.","groupIds":["OG000","OG001"],"nonInferiorityComment":"Arm B over Arm A","nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.61"}],"classes":[{"categories":[{"measurements":[{"comment":"Insufficient number of participants with events based on Kaplan-Meier Estimates","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Insufficient number of participants with events based on Kaplan-Meier Estimates","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"286"},{"groupId":"OG001","value":"296"}],"units":"Participants"}],"description":"Overall Survival (OS) is defined as the time from the randomization date to the date of death due to any cause. A participant who has not died will be censored at last known date alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab 240 mg infusion on Day 1 and every two weeks during cycles 1 and 2 for a total of 6 doses. Starting from Cycle 3 Day 1 participants received Nivolumab 480 mg infusion every 4 weeks.","id":"OG000","title":"Arm A - Nivolumab Monotherapy"},{"description":"Nivolumab 240 mg infusion followed by Ipilimumab 1 mg/kg IV on Day 1 and every three weeks during cycles 1 and 2 for a total of 4 doses. Starting from Cycle 3 Day 1, participants received Nivolumab 480 mg infusion every 4 weeks.","id":"OG001","title":"Arm B - Nivolumab + Ipilimumab"}],"paramType":"MEDIAN","populationDescription":"All randomized participants with centrally confirmed DNA mismatch repairdeficient/microsatellite instability-high metastatic colorectal cancer (dMMR/MSI-H mCRC) in Arm A and Arm B only","reportingStatus":"POSTED","timeFrame":"From randomization to the date of death due to any cause (Up to approximately 60 months)","title":"Overall Survival (OS) - Arm B vs. Arm A All Lines With dMMR/MSI-H mCRC","type":"SECONDARY","unitOfMeasure":"Months"}